SEC 13F Intelligence

Consonance Capital Management LP / KROS

Consonance Capital Management LP’s Keros Therapeutics Inc Position

Does Consonance Capital Management LP own Keros Therapeutics Inc (KROS)? Not currently — the last reported position was 887.9K shares worth $38M in Q2 2021; the fund’s latest 13F (Q3 2022) no longer reports it.

Position Value
$38M
Q2 2021
Shares
887.9K
% of Portfolio
+4.54%
Quarters Held
3
position exited

Position History KROS

Reported value by quarter
Q4 ’20: $39MQ4 ’20Q1 ’21: $55MQ1 ’21Q2 ’21: $38MQ2 ’21filingsflow.com
QuarterSharesValue% of Portfolio
Q2 2021887.9K$38M+4.54%
Q1 2021890.2K$55M+5.84%
Q4 2020557.1K$39M+3.67%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Consonance Capital Management LP’s full portfolio or all institutional holders of KROS.